The CurelineGroup and Cellecta, Inc. today announced the launch of Tissue 2 Target™ , a new strategic partnership to combine the companies’ core strengths in human biospecimen (HBS) management and molecular analysis of cells and tissues to offer services that streamline workflows for pre-clinical and translational research laboratories focusing on gene target and biomarker discovery.
The Tissue 2 Target partnership will provide a one-stop shop for researchers interested in molecular characterization of highly qualified human biospecimens to improve efficiency of pre-clinical and translational research workflows. The fusion of The Cureline Group’s foundation in human biospecimen (HBS) management with Cellecta’s capabilities in functional genomics techniques for drug target validation and biomarker discovery facilitates evidence-based decision-making to improve outcomes of translational and pre-clinical programs.
“I am very excited about our new partnership with Cellecta. Cureline’s global capabilities in HBS management and Cellecta’s exceptional assay development expertise will provide new great opportunities to ...
